Scarica l'app Stockscreener
15.12
1.18%
-0.18
Pre-mercato:
15.03
-0.09
-0.60%
Precedente Chiudi:
$15.30
Aprire:
$15.53
Volume 24 ore:
2.14M
Relative Volume:
1.46
Capitalizzazione di mercato:
$909.43M
Reddito:
$439.00K
Utile/perdita netta:
$-105.64M
Rapporto P/E:
-8.40
EPS:
-1.8
Flusso di cassa netto:
$-60.70M
1 W Prestazione:
-8.81%
1M Prestazione:
-48.36%
6M Prestazione:
-39.28%
1 anno Prestazione:
-75.26%
Intervallo 1D:
$14.85
$15.58
Intervallo di 1 settimana:
$14.85
$16.77
Portata 52W:
$14.85
$63.00
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Confronta JANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
15.12 | 920.26M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Wyckoff Accumulation Phase Possible in National Standard India LimitedBlue Chip Stock Analysis & Low Cost Capital Growth - earlytimes.in
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - AOL.com
Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Stempoint Capital LP Has $2.08 Million Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Jump Financial LLC Grows Stock Holdings in Janux Therapeutics, Inc. $JANX - MarketBeat
(JANX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Reassessing Janux Therapeutics (JANX) Valuation After Mixed Market Reaction to New JANX007 Phase 1 Data - Sahm
Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Yahoo Finance
Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential - TipRanks
Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Yahoo Finance
Andrew Hollman Meyer Sells 3,333 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Janux Therapeutics' (JANX) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Insider Sell: Andrew Meyer Sells Shares of Janux Therapeutics In - GuruFocus
What analysts say about Janux Therapeutics Inc stockFundamental Strength Indicators & High Return Investment Plans - earlytimes.in
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound - Stocktwits
Janux Therapeutics Sees Unusually Large Options Volume (NASDAQ:JANX) - MarketBeat
Analysts Unfazed By Janux’s Weaker Prostate Cancer Results - Citeline News & Insights
12/2/2025 Market UpdateWinners: XHLD, TLRY, HPPLosers: SONN, JANX, ABTCS&P 500: 0% - Trefis
Janux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data - Seeking Alpha
Stocks Edge Higher As Traders Wait For Key Inflation Data - Finimize
Bank of America Issues Pessimistic Forecast for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
Janux tanks despite claiming positive trial results for JANX007 in mCRPC - The Pharma Letter
Janux Therapeutics (NASDAQ:JANX) Given New $150.00 Price Target at Cantor Fitzgerald - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK), Alibaba Health Information Technology (OtherALBHF) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux reports positive phase 1 results for JANX007 in mCRPC; stock down - MSN
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy - geneonline.com
Janux shares halve despite still strong Phase I data - BioCentury
Janux stock falls as UBS maintains Buy rating despite disappointing data By Investing.com - Investing.com South Africa
Clear Street Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Stifel Maintains Janux Therapeutics (JANX) Buy Recommendation - Nasdaq
Janux Therapeutics stock price target lowered to $45 by H.C. Wainwright - Investing.com South Africa
Janux Therapeutics stock price target lowered to $150 by Cantor Fitzgerald - Investing.com Nigeria
Truist Securities reiterates Buy rating on Janux Therapeutics stock By Investing.com - Investing.com South Africa
Apple, Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Investor's Business Daily
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Stock Movers: Boeing, Janux Therapeutics, Signet - Bloomberg.com
Boeing, MongoDB, Credo, Warner Bros. Discovery, Janux, Ford, Marvell, and More Movers - Barron's
Investors flee Janux after updated prostate cancer results disappoint - FirstWord Pharma
Janux Therapeutics stock hits 52-week low at 18.34 USD By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Janux T-cell engager data sink stock, but analysts still see best-in-class potential - Fierce Biotech
Janux dives as gaps in prostate cancer study data worry investors - MSN
Janux Therapeutics Stock Hits 52-Week Low After Trial Update - inkl
Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair - BioPharma Dive
Janux stock falls as UBS maintains Buy rating despite disappointing data - Investing.com Nigeria
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):